CD209 and Miyoshi myopathy: Particularly we found that LEN, at concentrations reached in vivo in MM patients treated with this drug 5–25 mg daily, [27, 34] significantly increased the expression of DC maturation markers, HLA-DR, CD86 and CD209, that are involved in DC co-stimulatory function and trafficking, [35–37] both in BM and PB of MM patients.